Regentis Biomaterials CMO reports stock options
REGENTIS BIOMATERIALS LTD.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
REGENTIS BIOMATERIALS LTD. Chief Medical Officer Galit Reske reported initial holdings of an employee stock option to buy 67,961 shares of common stock. The option has a $4.00 exercise price and expires on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years. One-sixth of the option vests six months after the grant date, and one-twelfth vests on the last day of each subsequent three-month period, subject to continued employment.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Reske Galit
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Holdings:
Employee Stock Option (Right to Buy) — 67,961 contracts (Direct)
Footnotes (1)
- F1. This option was granted on February 23, 2026. The options shall vest on a quarterly basis, with one-sixth (1/6) of the options vesting upon the six-month anniversary of the grant date and one-twelfth (1/12) vesting on the last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date.
Key Figures
Underlying shares: 67,961 shares
Exercise price: $4.00 per share
Expiration date: February 23, 2037
+2 more
5 metrics
Underlying shares
67,961 shares
Employee stock option underlying common stock
Exercise price
$4.00 per share
Option exercise price for common stock
Expiration date
February 23, 2037
Option expiration
Grant date
February 23, 2026
Option grant to Chief Medical Officer
Vesting period
3 years
One-sixth at six months, then quarterly one-twelfth
Key Terms
Employee Stock Option (Right to Buy), exercise price, vesting, underlying security
4 terms
Employee Stock Option (Right to Buy) financial
"Security title is listed as Employee Stock Option (Right to Buy)."
exercise price financial
"The option has an exercise price of $4.0000 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options shall vest on a quarterly basis under the vesting schedule."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"The underlying security title is identified as Common Stock."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing by RGNT’s Chief Medical Officer report?
The Form 3 filing reports initial ownership of an employee stock option. It gives Galit Reske the right to buy 67,961 shares of REGENTIS BIOMATERIALS common stock at a $4.00 exercise price, expiring on February 23, 2037.
What is the exercise price and expiration date of the RGNT stock option?
The employee stock option has a fixed $4.00 exercise price per share and expires on February 23, 2037. This means Galit Reske can buy the vested shares at $4.00 any time before that expiration date, assuming the option has vested.
When was the RGNT stock option granted to the Chief Medical Officer?
The employee stock option was granted on February 23, 2026. This grant date starts the vesting schedule, including the six-month cliff before the first portion vests and the subsequent quarterly vesting periods described in the filing’s footnote.
How does the vesting schedule work for the RGNT employee stock option?
The option vests over three years. One-sixth vests on the six-month anniversary of the February 23, 2026 grant date, and one-twelfth vests on the last day of each following three-month period, contingent on continuous employment through each vesting date.
Is Galit Reske’s ownership of the RGNT stock option direct or indirect?
The filing shows direct ownership of the employee stock option. The derivative summary identifies the ownership type as direct, meaning the option is held personally, not through a trust, LLC, or other indirect entity structure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
